Aclarion Inc Stock Price, News & Analysis

Aclarion (NASDAQ: ACON) has announced the addition of Keck Medical Center of USC as a site for its CLARITY clinical trial. The trial aims to evaluate Nociscan, Aclarion's technology that uses biomarkers and AI algorithms to identify sources of chronic low back pain. The CLARITY study will enroll 300 patients across multiple US centers, including Johns Hopkins Medicine, Northwestern Medicine, Advocate Aurora Research Institute, and Texas Back Institute.

The randomized trial will assess patients scheduled for 1- or 2-level discogenic low back pain surgery, with surgeons either blinded or unblinded to Nociscan results at a 1:1 ratio. The primary endpoint is measuring change in back pain using a 100mm VAS Back scale at 12 months compared to baseline. Nociscan is positioned as the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful lumbar spine discs.

Aclarion (NASDAQ: ACON) has announced the addition of Texas Back Institute (TBI) as a new site for its CLARITY clinical trial. The trial aims to demonstrate the effectiveness of Nociscan, Aclarion's technology that uses MR Spectroscopy and AI to identify sources of chronic low back pain. The CLARITY study will enroll 300 patients across multiple US sites, including Johns Hopkins Medicine, Northwestern Medicine, and Advocate Aurora Research Institute.

The randomized trial will evaluate patients scheduled for 1- or 2-level discogenic low back pain surgery, with surgeons either blinded or unblinded to Nociscan results. The primary endpoint is measuring change in back pain after 12 months. Nociscan is positioned as the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful lumbar spine discs, targeting a global market of approximately 266 million people suffering from degenerative spine disease and low back pain.

Aclarion (NASDAQ: ACON) announced that Advocate Aurora Research Institute, part of Advocate Health, has joined as a site for their CLARITY trial. The trial aims to demonstrate the clinical and economic value of Nociscan, Aclarion's diagnostic platform that uses biomarkers and AI to identify sources of chronic low back pain.

The CLARITY trial is a prospective, randomized study that will enroll 300 patients across multiple US sites, evaluating surgical treatment of 1- or 2-level discogenic low back pain. The study will compare outcomes between surgeons who are blinded and unblinded to Nociscan results, with the primary endpoint measuring change in back pain at 12 months. Dr. Nicholas Theodore of Johns Hopkins Medicine serves as the principal investigator.

Aclarion (NASDAQ: ACON) has signed a commercial agreement with the Spine Institute of Louisiana (SIL), expanding its Nociscan technology to Louisiana. This marks Aclarion's first customer using Philips MR Spectroscopy (MRS), demonstrating the platform's integration capabilities across multiple systems.

Nociscan, a SaaS platform that helps physicians identify chronic low back pain sources, is now available at 17 sites across eight states and four countries. The technology boasts a 97% surgical success rate when treating all Nociscan-identified pain-positive discs.

Key highlights:

• SIL brings five board-certified, fellowship-trained surgeons to the partnership
• The institute has a research facility established in 2005 with national recognition
• Nociscan uses biomarkers and AI algorithms to noninvasively distinguish between painful and nonpainful discs
• The technology addresses a global healthcare challenge affecting approximately 266 million people with degenerative spine disease and low back pain

Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025. The presentation is scheduled for April 23, 2025, at 12:30 PM ET, where CEO Brent Ness will discuss the company and its recent value-driving initiatives. In conjunction with the event, the company has released an updated investor presentation available on their investor relations website.

Aclarion (NASDAQ: ACON) announced the publication of a peer-reviewed cost-effectiveness analysis of their Nociscan technology in Clinicoeconomics and Outcomes Research. The study demonstrates that Nociscan, a SaaS platform that helps identify chronic low back pain locations, is more cost-effective than traditional provocative discography.

The analysis reveals that Nociscan saves $1,712 per patient and improves surgical success rates by 10%. The technology uses biomarkers and AI algorithms to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine, addressing a global healthcare challenge affecting approximately 266 million people worldwide with degenerative spine disease and low back pain.

Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025.

CEO Brent Ness will deliver a presentation on Wednesday, April 23, 2025, at 12:30 PM ET and will be available for questions afterward. The company will also conduct in-person 1x1 investor meetings on Thursday, April 24, 2025, at the Paris Hotel & Casino in Las Vegas.

Aclarion (NASDAQ: ACON) has announced the expansion of its Nociscan product availability to the Medical Imaging Center of Southern California's (MICSC) Santa Monica location, extending beyond their existing Beverly Hills facility. Nociscan, a SaaS platform that helps physicians identify chronic low back pain locations through biomarkers and AI algorithms, was previously only available at MICSC's Beverly Hills center.

Dr. Bradley Jabour, MICSC's founder, was featured in a November 2024 article about Nociscan in MAGNETOM Flash, a Siemens Healthineers publication. The expansion into Santa Monica strengthens Aclarion's presence in Los Angeles, a strategic market with over 3.8M residents and the second-most populous city in the United States.

Nociscan is the first evidence-supported platform to noninvasively help physicians differentiate between painful and nonpainful lumbar spine discs by quantifying chemical biomarkers associated with disc pain.

Aclarion (NASDAQ: ACON) has strengthened its position following Q1 2025 strategic initiatives. The company raised over $20 million in Q1, maintaining nearly $15 million in cash with zero debt and no preferred equity. The company is now fully Nasdaq compliant, meeting both bid price and shareholder equity requirements.

The company's CLARITY trial for Nociscan, their AI-powered solution for identifying chronic low back pain locations, is fully funded with interim results expected in Q2 2026. Aclarion has secured additional payer approvals in England and expanded physician referral and commercial support in the U.S.

Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine, demonstrating a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated.